In a Phase II, randomized, multicenter prospective trial, intravenous glyburide failed to improve outcomes in patients with large hemispheric infarction, although there was a reduction in neuroimaging and biomarkers of cerebral edema.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content